276 related articles for article (PubMed ID: 34659899)
21. Asciminib for chronic myeloid leukaemia: Next questions.
Shanmuganathan N; Hughes TP
Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
23. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase.
Choi EJ
Blood Res; 2023 Apr; 58(S1):S29-S36. PubMed ID: 36891575
[TBL] [Abstract][Full Text] [Related]
24. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
[TBL] [Abstract][Full Text] [Related]
25. TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.
Valent P; Herndlhofer S; Schneeweiß M; Boidol B; Ringler A; Kubicek S; Gleixner KV; Hoermann G; Hadzijusufovic E; Müllauer L; Sperr WR; Superti-Furga G; Mannhalter C
Oncotarget; 2017 Apr; 8(14):23061-23072. PubMed ID: 28416739
[TBL] [Abstract][Full Text] [Related]
26. Management of TKI-resistant chronic phase CML.
Hughes TP; Shanmuganathan N
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):129-137. PubMed ID: 36485117
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
[TBL] [Abstract][Full Text] [Related]
28. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
Yeung DT; Shanmuganathan N; Hughes TP
Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
[TBL] [Abstract][Full Text] [Related]
29. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
30. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
[TBL] [Abstract][Full Text] [Related]
31. Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy.
Zhou L; Shi H; Shi W; Yang L; Zhang Y; Xu M; Chen X; Zhu Y; Mu H; Wan X; Yang Z; Zeng Y; Liu H
Onco Targets Ther; 2019; 12():10989-10995. PubMed ID: 31997880
[TBL] [Abstract][Full Text] [Related]
32. Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
Combes FP; Li YF; Hoch M; Lorenzo S; Ho YY; Sy SKB
Clin Pharmacol Ther; 2022 Nov; 112(5):1040-1050. PubMed ID: 35776072
[TBL] [Abstract][Full Text] [Related]
33.
Heatley SL; Asari K; Schutz CE; Leclercq TM; McClure BJ; Eadie LN; Hughes TP; Yeung DT; White DL
Leuk Lymphoma; 2021 May; 62(5):1157-1166. PubMed ID: 33390067
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1.
Zhang H; Zhu M; Li M; Ni D; Wang Y; Deng L; Du K; Lu S; Shi H; Cai C
Front Pharmacol; 2022; 13():862504. PubMed ID: 35370687
[TBL] [Abstract][Full Text] [Related]
35. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
36. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Zabriskie MS; Eide CA; Tantravahi SK; Vellore NA; Estrada J; Nicolini FE; Khoury HJ; Larson RA; Konopleva M; Cortes JE; Kantarjian H; Jabbour EJ; Kornblau SM; Lipton JH; Rea D; Stenke L; Barbany G; Lange T; Hernández-Boluda JC; Ossenkoppele GJ; Press RD; Chuah C; Goldberg SL; Wetzler M; Mahon FX; Etienne G; Baccarani M; Soverini S; Rosti G; Rousselot P; Friedman R; Deininger M; Reynolds KR; Heaton WL; Eiring AM; Pomicter AD; Khorashad JS; Kelley TW; Baron R; Druker BJ; Deininger MW; O'Hare T
Cancer Cell; 2014 Sep; 26(3):428-442. PubMed ID: 25132497
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
[TBL] [Abstract][Full Text] [Related]
38. The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.
G Lindström HJ; Friedman R
BMC Cancer; 2020 May; 20(1):397. PubMed ID: 32380976
[TBL] [Abstract][Full Text] [Related]
39. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
[TBL] [Abstract][Full Text] [Related]
40. Resistant mutations in CML and Ph(+)ALL - role of ponatinib.
Miller GD; Bruno BJ; Lim CS
Biologics; 2014; 8():243-54. PubMed ID: 25349473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
